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Background: Non-small cell lung cancer (NSCLC) expressed high levels of epidermal growth factor receptor (EGFR).
Gefitinib (Iressa) has demonstrated clinical efficacy in NSCLC patients harboring EGFR mutations or refractory to
chemotherapy. However, most of NSCLC patients are with wild type EGFR, and showed limited response to
gefitinib. Therefore, to develop new effective therapeutic interventions for NSCLC is still required. Our previous
study showed Marsdenia tenacissima extract (MTE) restored gefitinib efficacy in the resistant NSCLC cells, but
whether MTE acts in the gefitinib-sensitive NSCLC cells is the same as it in the resistant one is unknown.
Methods: Dose response curves for gefitinib and MTE were generated for two sensitive NSCLC cell lines with
mutant or wild type EGFR status. Three different sequential combinations of MTE and gefitinib on cell growth were
evaluated using IC50 and Combination Index approaches. The flow cytometric method was used to detect cell
apoptosis and cell cycle profile. The impact of MTE combined with gefitinib on cell molecular network response
was studied by Western blotting.
Results: Unlike in the resistant NSCLC cells, our results revealed that low cytotoxic dose of MTE (8 mg/ml)
combined gefitinib with three different schedules synergistically or additively enhanced the growth inhibition of
gefitinib. Among which, MTE→MTE + gefitinib treatment was the most effective one. MTE markedly prompted cell
cycle arrest and apoptosis caused by gefitinib both in EGFR mutant (HCC827) and wild type of NSCLC cells (H292).
The Western blotting results showed that MTE→MTE + gefitinib treatment further enhanced the suppression of
gefitinib on cell growth and apoptosis pathway such as ERK1/2 and PI3K/Akt/mTOR. This combination also blocked the
activation of EGFR and c-Met which have cross-talk with each other. Unlike in gefitinib-resistant NSCLC cells, MTE alone
also demonstrated certain unexpected modulation on EGFR related cell signal pathways in the sensitive cells.
Conclusion: Our results suggest that MTE is a promising herbal medicine to improve gefitinib efficacy in NSCLC
regardless of EGFR status. However, why MTE acted differently between gefitinib-sensitive and -resistant NSCLC cells
needs a further research.
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Lung cancer is the leading cause of cancer death world-
wide. The high mortality of lung cancer is related to the
fact that most patients present with metastatic disease for
which there is no curative therapy. Non-small cell lung
cancer (NSCLC) accounts for 75% - 80% of all lung can-
cers [1]. Epidermal growth factor receptor (EGFR) is a
family member of EGF-related tyrosine kinase receptors,
and expressed at high levels in many cancer cell types, in-
cluding NSCLC [2]. This leads to inappropriate activation
of the downstream signalling cascade, eventually leading to
uncontrolled cell proliferation [3]. Studies showed EGFR
is overexpressed in up to 80% of NSCLC and become a
promising target for anti-cancer therapy [4,5].
An orally active tyrosine kinase inhibitor (TKI), gefi-
tinib (ZD1839, Iressa), competes with ATP for the bind-
ing sites at tyrosine kinase domain, thereby dampening
the phosphorylation and activation of EGFR so as to the
downstream signaling network [6,7]. Gefitinib has been
shown to significantly improve progression-free survival
and used extensively for the first-line therapy in advanced
NSCLC patients harboring EGFR mutations [8,9]. Exon 19
deletion mutations and L858 mutation in exon 21 of
EGFR increase gefitinib sensitivity in NSCLC [10,11].
However, only 10% - 20% NSCLC patients with wild type
of EGFR responded to gefitinib [12,13]. Moreover, clinical
study revealed that NSCLC patients with EGFR mutations
have a significantly longer survival than those with wild-
type EGFR when treated with EGFR TKIs [14]. Despite
experiencing dramatic clinical responses, patients who ini-
tially respond to gefitinib eventually develop progressive
disease or incomplete cross-resistance to the currently
available EGFR-TKIs like erlotinib [15,16]. Therefore, how
to improve gefitinib efficacy and let more NSCLC patietns
gain benefit from TKI therapy is still the goal of physicians
and researchers.
Marsdenia tenacissima (Roxb.) Wight et Arn., which
mainly produced in Yunnan province of China, has long
been used as a remedy to treat cancer in China [17]. More
than 40 C-21 steroidal glycosides have been isolated from
the stem of M. tenacissima [18]. C-21 steroids have previ-
ously been shown to be cytotoxic in cancer cell lines [19]
suggesting that C-21 steroids are responsible for the anti-
cancer activities of M. tenacissima. Thirteen of the C-21
steroid compounds were identified in MTE by HPLC-MS/
MS analysis [20]. Xiao-Ai-Ping injection, a water extract
of M. tenacissima, has been proposed as a potential agent
in the management of tumors, which is clinically effective
in treatment of NSCLC when combined with chemother-
apy [21-23]. Commonly, the treatment dosage of Marsde-
nia tenacissima extract (MTE) for cancer patients is
between 20 ml to 100 ml (equals to 20 ~ 100 g crude drug)
per day according to the manufacture’s instruction. Ac-
cording to our previous study, MTE restores gefitinibsensitivity in the resistant NSCLC cells and the mechanisms
may be partially due to the down-regulation of PI3K/Akt/
mTOR and ERK1/2 and inhibition of c-Met phosphoryl-
ation [20]. However, whether MTE could enhance gefitinib
efficacy in the sensitive NSCLC cells is unknown, and
whether the mode of action of MTE show difference or just
the same in gefitinib-sensitive and -resistant NSCLC cells.
Therefore, the present study was to evaluate the regimen
of MTE sequential combination with gefitinib against
gefitinib-sensitive NSCLC cells, HCC827 (EGFR mutant)




Human NSCLC cell lines HCC827 (epithelial adenocar-
cinoma) and H292 (alveolar epithelial carcinoma) were
purchased from American Type Culture Collection
(Manassas, Virginia, USA). H292 cells contains wild-
type EGFR, whereas HCC827 bearing EGFR exon 19 dele-
tion [24]. Cells were maintained in RPMI-1640 (Gibco)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Gibco), 100 units/ml penicillin, and 100 μg/ml
streptomycin at 37°C and 5% CO2.
Drug treatment
Gefitinib was purchased from AstraZeneca (Cheshire,
UK). Stock solution was prepared in dimethyl sulfoxide
(DMSO) at 20 mM and stored at −20°C. MTE (M. tena-
cissima extract, trade name: Xiao-Ai-Ping injection) (1 g
crude/ml) was produced by SanHome Pharmaceutical Co.,
Ltd (NanJing, China). When the cells were treated with
MTE or gefitinib, the MTE solvent or 0.5% DMSO was
used as the negative control accordingly.
Antibodies and reagents
The specific antibody of EGFR, p-EGFR (Tyr1068), p-
PI3K, Akt, mTOR, p-mTOR (Ser2448), Met, p-Met
(Y1234/1235), ERK1/2, p-ERK1/2, β-actin and β-tubulin
were purchased from Cell Signaling Technology (Beverly,
MA). PI3K and p-Akt (Ser473) were obtained from
ABcam (Cambridge, UK). The enhanced chemilumines-
cence (ECL) system was from Millipore (Millipore, MA,
USA). Epidermal growth factor (EGF) was purchased from
Biosource International Inc. (Camarillo, CA) and dissolved
in phosphate-buffered saline (PBS).
Cell viability assay
The cell viability was measured by MTT assay. In brief,
cells were plated in 96-well culture plates at the density of
1 ~ 1.5 × 104 per well in complete medium. After 24 h in-
cubation, cells were treated with gefitinib (0.001 ~ 50 μM)
or MTE (0.5 ~ 500 mg/ml) for 72 h. The optical density at
570 nm was measured and the IC50 value was calculated
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pad Prism 4.0 software (San Diego, CA).
Sequential combination effect evaluation
Cells were plated in 96-well culture plates and incubated
for 24 h, then started treatment by following three differ-
ent sequential combinations described previously [20,25]:
(1) first pretreated cells with MTE for 12 h and then added
gefitinib to MTE-containing medium for another 72 h
(M→M+G); (2) MTE and gefitinib were added concur-
rently to the medium and incubated for 72 h (M+G); (3)
first pretreated with gefitinib for 12 h and then added
MTE to gefitinib-containing medium for another 72 h
(G→G+M). Each sequential combination of MTE and
gefitinib was characterized by a combination index (CI) as
described by Chou [26] and calculated with CompuSyn
(ComboSyn, Inc., Paramus, NJ, USA). The CI values were
interpreted as follows: CI: 0.1-0.3 strong synergism, CI: 0.3-
0.7 synergism, CI: 0.7-0.85 moderate synergism, CI: 0.85-
0.9 slight synergism, CI: 0.9-1.1 nearly additive, and CI > 1.1
antagonism.
Cell cycle analysis
H292 or HCC827 cells were pretreated with MTE for
12 h and then co-treated with or without gefitinib for
another 72 h. Cells were detached with 0.25% EDTA-
trypsin (Gibco), washed with PBS and fixed with ice-
cold 70% ethanol overnight at 4°C. Cells were washed
with PBS and incubated with RNase A (100 μg/ml) at
37°C for 30 min. DNA was labeled with PI (50 μg/ml) and
the fluorescence was measured with a FACScalibur flow
cytometer (Becton Dickinson). Data collection and ana-
lysis of the cell cycle distribution were performed using
CellQuest and the Modfit software (Becton Dickinson).
Detection of apoptosis by flow cytometry
H292 or HCC827 cells were pretreated with MTE for 12 h
and then co-treated with or without gefitinib for another
72 h. Floating and adherent cells were collected and sus-
pended in PBS, labeled with Annexin V and propidiumio-
dide (PI) following the manufacturer’s instruction (Biosea
Biotechnology, Beijing, China). Flow cytometry (Bection
Dikinson, USA) was used to assess the apoptotic cells. The
quantitation of apoptotic cells was calculated by CellQuest
software.
Western blot analysis
After different drug treatment, the cells were stimulated
with 10 ng/ml EGF for 15 min before harvesting, washed
twice with cold PBS and lysed with RIPA buffer that con-
taining protease and phosphotase inhibitors cocktail
(Roche, UK). The supernatants were collected after centri-
fugation at 12000 rpm for 20 min. The protein was
applied to polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a PVDF membrane, and then de-
tected by the proper primary and secondary antibodies
before visualization with a chemiluminescence kit. The
intensity of blot signals was quantitated using Image-
Quant TL analysis software (General Electric, UK).
Statistical analysis
All data were expressed as means ± standard error of the
mean (SEM) obtained from at least three independent ex-
periments. Statistical comparisons between experimental
and control groups were assessed by using the Student’s t-
test. P < 0.05 was considered statistically significant.
Results
Anti-proliferative activity of gefitinib and MTE in
NSCLC cells
We examined the in vitro cell growth inhibition of gefitinib
or MTE on NSCLC cells by using MTT assay. After treat-
ment for 72 h, the IC50 value for gefitinib was 0.166 μM for
H292 cells (EGFR wild type), and 0.015 μM for HCC827
cells (EGFR exon 19 deletion) (Figure 1A), indicating they
are gefitinib-sensitive cell lines. H292 carrying wild-type
EGFR but highly sensitive to gefitinib, suggesting that there
exists off-target(s) of gefitinib in addition to the commonly
accepted target EGFR, which deserves a further investiga-
tion. When exposed to MTE, these two cell lines showed a
similar dose-dependent inhibition manner on cell viability
regardless of the EGFR status (Figure 1B). The IC50 value of
MTE was 46.62 mg/ml for H292 cells and 48.78 mg/ml for
HCC827 cells, respectively.
Sequential-combined inhibitory effect of gefitinib and
MTE in NSCLC cells
The effect of sequential combination of gefitinib and
MTE was examined in H292 and HCC827 cells. In the
following experiments, MTE is set at a concentration of
8 mg/ml for HCC827 and H292 cells (approximately
IC15 value). At this concentration, MTE showed only
weak inhibition of cell growth with the cell viability ap-
proximately 90%. Compared with gefitinib or MTE
alone, all cells treated with gefitinib plus MTE exhibited
decreased viability (Figure 2A and B). The combination
index (CI) values were calculated by CompuSyn soft-
ware as described in Materials and Methods. Linear cor-
relation coefficients (r values) for all curves were >0.95,
indicating a high goodness of fit. As shown in Figure 2C,
the CI values in H292 cells treated by G +M and M→
M+G were all <1, indicating that there was a synergis-
tic interaction between gefitinib and MTE in these two
sequential combinations. The CI values in G→G +M
treated H292 cells predicted antagonism at the lowest
gefitinib concentration but nearly additive to synergistic
effects at other high concentrations. In Figure 2D, CI
values in HCC827 cells treated by three different
Figure 1 Treatment of non-small cell lung cancer cells with gefitinib or MTE (M. tenacissima extract) reduced their proliferation
potential. (A) H292 and HCC827 cells were treated with the indicated concentrations of gefitinib for 72 h. (B) H292 and HCC827 cells were
treated with the indicated concentrations of MTE for 72 h. Cells viability was determined by using the MTT assay as described in the Methods
section. The data are expressed in terms of percent of control cells as the means ± SEM. The experiments were repeated at least three times.
*P < 0.05, **P < 0.01 vs. control group.
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were in H292 cells, but the synergism effects were even
more pronounced. Among the three different combina-
tions, the M→M+G treatment was potent over the
other two sequential combinations both in H292 and
HCC827 cells, indicating this was the preferred combin-
ation of gefitinib and MTE.
MTE affected gefitinib on cell cycle distribution
The effect of MTE combined with gefitinib on cell cycle
distribution was examined with flow cytometry. As
shown in Figure 3A, MTE treatment caused increase at
G2/M phase (from 10.7% to 13.2%) and decrease at G0/
G1 phase (from 71.7% to 67.0%) in H292 cells when
compared with control group. The fraction cells in G2/
M phase were significantly elevated to 18.6% and the
proportion of G0/G1 phase cells was depressed to 62.5%
by gefitinib alone. Moreover, MTE→MTE +Gef treat-
ment further raised the percentage of G2/M phase cells
to 22.9% and reduced G0/G1 phase cells to 60.7%. The
results above suggested that MTE enhanced gefitinib in-
duced G2/M arrest in H292 cells.
Compared with control group, it showed that HCC827
cells treated with MTE induced accumulation in the S
phase of cell cycle from 21.5% to 23.9% while G2/M phase
cells decreased from 16.7% to 14.1%. 1 μM gefitinib
treated HCC827 cells were markedly accumulated in the S
phase of cell cycle to 26.6% and the G2/M phase cells were
decreased to 11.7%. The percentage of G2/M-phase cells
was further decreased to 9.6% in the MTE→MTE +Gef
group, and induced a significant cell population in S phase
to 31.0% (Figure 3B). This finding indicates that cell cycle
distribution was blocked significantly in the S phase when
HCC827 cells were treated with MTE combined withgefitinib. Accumulation in the sub-G1 phase of cell
cycle were observed both in H292 and HCC827 cells,
suggesting the sequential events of cell cycle arrest
followed by apoptosis.
MTE enhanced gefitinib-induced apoptosis in NSCLC cells
To examine the mechanism of inhibitory effect of MTE
combined with gefitinib, cell apoptosis was performed
by flow cytometry. The final concentration of gefitinib
used in the treatments was 1 μM because it closes to the
serum level observed in patients being treated with gefi-
tinib [27]. Apoptotic cell death was determined in terms
of early- or late-stage apoptotic cells, which are shown
respectively in the lower right and upper right quadrants
of the FACS histograms (Figure 4A). Treatment of H292
and HCC827 cells with gefitinib and MTE alone or in
combination induced a substantial fraction of apoptosis.
The percentage of total apoptotic cells (including early and
late stage) in H292 cells after different treatment was as fol-
lows: 5.8% (vehicle-treated control), 12.4% (MTE 8 mg/ml),
27.4% (gefitinib 1 μM), and 66.5% (MTE→MTE+Gef,
M→M+G) (Figure 4). Similar tendency of apoptosis was
observed in HCC827 cells as shown in Figure 4A and 4B.
The combined treatment of MTE and gefitinib further en-
hanced cell apoptosis that induced by gefitinib in H292 and
HCC827 cell lines, and showed significant difference with
each drug alone (P < 0.05). The results revealed that M→
M+G treatment was effective in cell apoptosis induction.
MTE affected EGFR downstream pathways inhibition
by gefitinib
The major pathways activated by EGFR-TK are the Ras-
Raf-MEK-ERK pathway (leading to cell growth), the
mTOR pathway (leading to protein synthesis), and the
Figure 2 MTE (M. tenacissima extract) enhances gefitinib induced cytotoxicity in gefitinib-sensitive non-small cell lung cancer cell lines.
H292 (A) or HCC827 (B) cells were incubated with increasing concentrations of gefitinib and MTE alone or different schedule combinations.
Treatment schedule: (1) M→M+ G, MTE pretreated for 12 h, then M + G (MTE + gefitinib) for another 72 h. (2) M + G, MTE and gefitinib
concomitantly treated for 72 h. (3) G→ G +M, gefitinib pretreated for 12 h, then G +M (gefitinib + MTE) for another 72 h. Growth assays were
performed by MTT assay and IC50 values were calculated by Graphpad Prism 5.0 software (San Diego, CA, USA). CI values for the combinations of
gefitinib and MTE in H292 (C) and HCC827 (D) cells were calculated using the Calcusyn software (Cambridge, UK), as described in the Methods
section. Each data point represented the mean of 3 to 4 replicates; r values for all curves were >0.95. *P < 0.05, **P < 0.01 vs. control group.
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apoptosis). To investigate the combined effects of MTE
and gefitinib on EGFR-dependent signaling pathways,
cells were stimulated with 10 ng/ml EGF for 15 minutes
before harvest. We found EGF stimulated the activation of
PI3K/Akt/mTOR and ERK1/2, and their phosphorylation
extent is much higher in HCC827 cell (EGFR mutant)
than H292 cells (EGFR wide type) (Figure 5). The activa-
tion of EGFR downstream pathways was strongly inhibited
by gefitinib treatment. Treated with MTE moderatelyreduced PI3K/Akt/mTOR and ERK1/2 phosphorylation
with a similar profile in H292 and HCC827 cells. More-
over, the inhibition was further enhanced by treatment of
M→M+G and blocked PI3K/Akt/mTOR and ERK1/2
signaling pathways.
MTE enhanced EGFR and c-Met inhibition by gefitinib
c-Met and EGFR receptors are widely expressed in cancer
cells. The c-Met receptor tyrosine kinase has a central role










































































Figure 3 MTE (M. tenacissima extract) enhances gefitinib induced delay in cell cycle in non-small cell lung cancer cell lines H292 (A)
and HCC827 (B). Cells were treated with 1 μM gefitinib, 8 mg/ml MTE, and their combination (MTE→MTE + Gef, M→M+ G) in 1% FBS culture
medium for 72 h, then harvested, ethanol fixed and labeled with PI for the analysis of cell cycle by FACS analysis. Each data presented as the
means ± SEM of three experiments. *P < 0.05; **P < 0.01vs vehicle control group, aP < 0.05 vs MTE treated group, bP < 0.05 vs gefitinib
treated group.
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that EGFR activation contributes to c-Met tyrosine phos-
phorylation [29]. Our results showed EGF slightly stimu-
lated the phosphorylation of c-Met and EGFR in H292
and HCC827 cells (Figure 6). However, gefitinib alone or
combined with MTE totally blocked the phosphorylation
of c-Met and EGFR in these two NSCLC cells. This is in
consistent with other research that gefitinib simultan-
eously inhibited both EGFR and c-Met phosphorylation in
gefitinib-sensitive NSCLC cells [30]. Moreover, the activa-
tion of EGFR and c-Met was also significantly inhibited by
MTE treatment alone as shown in Figure 6. The inhibitionon EGFR and c-Met phosphorylation may partly explain
the underlying mechanisms of MTE on EGFR-TKI sensi-
tive NSCLC.
Discussion
The two primary signaling pathways activated by EGFR
include the Ras/Raf/MEK/ERK and the PI3K/Akt axes
[31]. In the understanding of the nature of NSCLC car-
cinogenesis, EGFR-TKIs become an innovative approach
for NSCLC patients to achieve more effective treatment.
Gefitinib exerted anti-tumor effect by inhibiting EGFR-
driven signaling activation such as Akt and ERK1/2 in the
Figure 4 MTE (M. tenacissima extract) prompts apoptosis induced by gefitinib in non-small cell lung cancer cells. (A) H292 and HCC827
cells were treated with 1 μM gefitinib, 8 mg/ml MTE, and their combination (MTE→MTE + Gef, M→M+G) in 1% FBS culture medium for 72 h,
then harvested and labeled with Annexin V-PI for the analysis of apoptotic cells by FACS analysis. The lower right quadrant and the upper right
quadrant of the FACS histograms indicate the percentage of early and late apoptotic cells, respectively. (B) Total percentages of apoptotic cells in
each treatment group are summarized with data presented as the means ± SEM of three experiments. *P < 0.05; **P < 0.01vs vehicle control group,
aP < 0.05 vs MTE treated group, bP < 0.05 vs gefitinib treated group.
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inhibited EGFR and its downstream signaling pathways
such as PI3K/Akt/mTOR and ERK in gefitinib-sensitive
NSCLC cells, HCC827 and H292, as expected. However,
in the resistant NSCLC cells, EGFR is not a survival factor
and other factor driven cell survival following activation of
downstream signaling effectors was dominant [32].
Nowadays, the use of herbal medicines or compounds
from them is becoming increasingly popular, and provides
alternative treatment options for cancer patients [33]. It has
been demonstrated that curcumin potentiates the antitu-
mor activity of gefitinib in NSCLC cell lines and xenograftmice model [34]. Co-treatment with gefitinib and epigallo-
catechin gallate (EGCG), a green tea polyphenol, synergis-
tically suppressed the metastatic ability of CAL-27 human
oral squamous cell carcinoma cells [35]. We previously re-
ported that M. tenacissima extract (MTE, Xiao-Ai-Ping in-
jection) restored gefitinib sensitivity in the resistant NSCLC
cells through synergistic inhibition of PI3K/Akt/mTOR,
ERK1/2 activation and c-Met phosphorylation [20]. In the
present study, human NSCLC cell line HCC827 and H292
cells were very sensitive to gefitinib with IC50 at 0.015 μM
and 0.166 μM, respectively. MTE was also cytotoxic to
HCC827 and H292 cells when treated alone. Compared to
Gefitinib (1μM)
MTE (8 mg/ml )
EGF (10 ng/ml ) – +         +         +         +
– – +          – +
– – – +         +
H292
– +         +         +         +
– – +          – +
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Figure 5 MTE (M. tenacissima extract) enhances the inhibition of gefitinib on PI3K/Akt/mTOR and ERK1/2 signaling cascade in
non-small cell lung cancer cells. H292 and HCC827 cells were treated with 1 μM gefitinib, 8 mg/ml MTE, and their combination (MTE→MTE + Gef,
M→M+G) in 1% FBS culture medium for 6 h. Cells were stimulates with 10 ng/ml EGF for 15 min before harvest. Cells were lysed and cellular
extracts (20 μg protein) were separated on SDS-PAGE gel and transferred to PVDF membranes. (A) Membranes were probed with PI3K, phospho-PI3K,
Akt and phospho-Akt; (B) Membranes were probed with mTOR, phospho-mTOR, ERK1/2 and phospho-ERK1/2. Blots are representatives of three
independent experiments. Relative density of proteins were calculated and normalized based on β-tubulin or β-actin.
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bined gefitinib and MTE treatment synergistically or
additively suppressing cell viability regardless of the se-
quential difference. Among which, the MTE→MTE +Gef treatment showed more potent on decreasing cell
growth than the other combinations, concurrent admin-
istration and Gef → Gef +MTE. Furthermore, the en-
hanced cell proliferation inhibition by MTE→MTE +
Gefitinib (1μM)
MTE (8 mg/ml )
EGF (10 ng/ml ) – +         +         +         +
– – +          – +
– – – +         +
H292
– +         +         +         +
– – +          – +







0.96         1         0.0        0.31      0.0 0.90        1        0.02      0.20      0.01
0.90        1        0.0       0.19      0.0 0.76        1        0.0       0.08      0.0
p-Met/Met
p-EGFR/EGFR
Figure 6 MTE (M. tenacissima extract) combined with gefitinib reduces EGFR and Met crosstalk in non-small cell lung cancer cells. H292
and HCC827 cells were treated with 1 μM gefitinib, 8 mg/ml MTE, and their combination (MTE→MTE + Gef) in 1% FBS culture medium for 6 h.
Cells were stimulates with 10 ng/ml EGF for 15 min before harvest. Cells were lysed and cellular extracts (20 μg protein) were separated on
SDS-PAGE gel and transferred to PVDF membranes. Membranes were sequentially probed with Met, phospho-Met, EGFR and phospho-EGFR.
β-tubulin was served as a loading control. Blots are representatives of three independent experiments.
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This is in accordance with our previous result that MTE→
MTE+Gef had potential effect against gefitinib-resistant
NSCLC cell lines [20]. However, it was very interesting that
the Gef → Gef +MTE schedule was also effective in redu-
cing proliferation of H292 and HCC827 cells, whereas an
antagonistic effect was observed in the resistant cells, H460
and H1975. The underlying reasons for Gef →Gef +MTE
acts different in gefitinib-resistant and -sensitive NSCLC
cells deserve a further research. MTE also could enhance
the tumor growth inhibitory effect of erlotinib, another
common used TKI, by the three different combination pro-
cedures (see Additional file 1). In other studies, the exhib-
ited synergistic or additive effects by different reagents
combinations were also demonstrated. Paclitaxel followed
by gefitinib was regarded as an effective treatment combin-
ation for NSCLC cell lines harboring EGFR mutations [36],
while schedule-dependent synergistic effect was seen in the
combinations of gefitinib and irinotecan in lung cancer cell
lines [25].
Flow cytometric data revealed MTE and gefitinib alone
or in combination caused different cell cycle arrest in
H292 and HCC827 cells. They clearly induced G2/M ar-
rest in H292 cells but caused S phase block in HCC827
cells, and this discrepancy may due to cell characteristics
difference. The combination of MTE→MTE + gefitinib
enhanced cell cycle arrest and apoptosis that induced bygefitinib in NSCLC cell lines and showed significant differ-
ence with each drug alone (P < 0.05). Taken together, these
findings in part suggest that MTE→MTE +Gef could in-
hibit the growth of H292 and HCC827 cells by inducing
cell cycle arrest and apoptosis, and induction of apoptosis
was seems to be more important in this study.
Over activation of ERK which is one of the main cell
proliferation and survival factors. Studies showed that
constitutive ERK1/2 activity in NSCLC cells promotes
cellular survival and chemotherapeutic resistance [37].
In our research, the phosphorylation of ERK was signifi-
cantly suppressed by gefitinib. MTE also decreased ERK
activation to some extent. The combination of MTE→
MTE +Gef treatment enhanced the inhibition of gefi-
tinib on H292 and HCC827 cell growth. This prominent
suppression of cell proliferation was correlated with an
enhanced inhibition on ERK1/2 activation by the com-
bination of MTE→MTE +Gef.
The PI3K/Akt/mTOR is an important intracellular
signaling pathway in cell apoptosis, and this deregu-
lated cascade is reported to contribute to lung cancer
development and maintenance [38]. Frequent Akt acti-
vation and mTOR phosphorylation were found in 51%
of NSCLC patients and in 74% of NSCLC cell lines
[39]. NSCLC cell lines responsive to EGFR TKIs with
growth arrest or apoptosis showed a down-regulation
of the PI3K/Akt/mTOR pathway [40]. In this study,
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Akt/mTOR. MTE alone also moderately decreased the
phosphorylation of these signaling molecules at a rela-
tive low concentration used in the study (~IC15, 8 mg/ml).
Furthermore, MTE→MTE +Gef treatment acted syner-
gistically in disruption of the PI3K/Akt/mTOR signaling
cascade and induction of apoptosis in H292 and HCC827
cells.
c-Met and EGFR receptors are widely expressed in
cancer cells, and they have redundant effects on cell
cycle progression, apoptosis, motility and metastasis
and are potential targets for combination therapy. There
is a cross-talk between the c-Met and EGFR signaling
pathways in lung cancer [29]. EGFR and c-Met kinase
activity is required for EGF-induced c-Met phosphoryl-
ation. The present study showed treatment with gefi-
tinib abolished tyrosine phosphorylation of c-Met and
EGFR as it demonstrated in other research [29,41]. Of
course, the combination of MTE and gefitinib further
decreased c-Met and EGFR phosphorylation. To our
surprise, MTE alone at a relative minimal cytotoxic
concentration also decreased c-Met and EGFR phos-
phorylation very strongly in the present study, suggest-
ing it could inhibit both of these two growth factor
receptors. However, MTE alone only showed inhibition
tendency in the resistant cells according to our previous
experiment [20]. The same phenomenon was also ob-
served in above mentioned PI3K/Akt/mTOR pathway
and ERK1/2. It suggests that MTE acted differently in
gefitinib-sensitive and -resistant NSCLC cells. But what
factors resulted in the difference of MTE activity is an
interesting issue and needs a further study.
Conclusion
In summary, we have found MTE and gefitinib acted
synergistically or additively with different combina-
tions to suppress gefitinib sensitive NSCLC cell
growth over treatments with either agent alone. Mean-
while, the cell cycle arrest and apoptotic cells were
greatly promoted by MTE→MTE + Gef treatment,
the most powerful combination. The underlying me-
chanisms of this remarkable cell growth inhibition
were mostly ascribed to the significant suppression of
ERK1/2 and PI3K/Akt/mTOR. The blocked crosstalk
of EGFR and c-Met was also contributed to the prom-
inent anti-tumor effect of MTE→MTE + Gef treat-
ment. However, there was no obvious difference
between the effect of this combination in EGFR mu-
tant cell line HCC827 and wild type cell line H292.
Thus, our results suggest that MTE is a promising herbal
medicine to improve gefitinib efficacy in NSCLC regar-
dless of EGFR status. The different effect of MTE in
gefitinib-sensitive and -resistant NSCLC cells needs fur-
ther research.Additional file
Additional file 1: MTE (M. tenacissima extract) enhances erlotinib
induced cytotoxicity in gefitinib-sensitive non-small cell lung cancer
cell lines H292 (A) and HCC827 (B). Treatment schedule: (1) M → M +
E, MTE pretreated for 12 h, then M + E (MTE + erlotinib) for another 72 h.
(2) M + E, MTE and erlotinib concomitantly treated for 72 h. (3) E → E +
M, erlotinib pretreated for 12 h, then E + M (erlotinib + MTE) for another 72
h. CI values were calculated using the Calcusyn software (Cambridge, UK), as
described in the Methods section. *P < 0.05, **P < 0.01 vs. control group.
Abbreviations
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